Impact of HCV antiviral therapy on the Liver Transplantation Waiting-List assessed by mathematical models

Eleazar Chaib1*, João Luís Erbs Pessoa2, Marizete Medeiros2 and Eduardo Massad3

1Department of Gastroenterology, Division of Liver Transplantation, University of São Paulo, 01246-903, Sao Paulo, Brazil
2State Secretary of Health, 05403-000, Sao Paulo, SP, Brazil
3School of Applied Mathematics, Fundação Getulio Vargas, 22250-900, Rio de Janeiro, RJ, Brazil

Received: 05 December, 2018
Accepted: 02 January, 2019
Published: 03 January, 2019

*Corresponding author: Eleazar Chaib, M.D, PhD, FRCS, Associate Professor of Surgery, School of Medicine, University of São Paulo, Av. Dr. Arnaldo 455, 3rd floor, suite 3208, 01246-903, São Paulo, Brazil, Tel: +55 11 30618319; Fax: +55 11 30617270; E-mail: eleazar.chaib@yahoo.co.uk

Keywords: Hepatites C; Antiviral treatment; Waiting list; Liver transplantation

Introduction

Prevalence of hepatitis C virus (HCV) infection is found worldwide however country prevalence ranging from less than 1% to greater than 10%. The highest prevalence has been reported in Africa and Middle-East, with a lower prevalence in the Americas, Australia, and Northern and Western Europe [1].

Sao Paulo is the first Brazilian state to perform liver transplantation in 1968 [2]. Since then the recipient waiting list has increased; now approximately 150 new cases per month are referred to the single list at the central organ procurement organization [3]

HCV infection is considered a major public health problem [4], with a global prevalence rate of 2.8%, equating to over 185 million infections, and more than 350,000 deaths annually.

An estimated 3 million to 4 million new cases of HCV infection emerge every year, worldwide [5]. Furthermore, the HCV-related mortality is increasing and HCV infection is projected to be the most important leading cause of viral hepatitis-related mortality in the near future [4,6].

End-stage liver disease due to HCV is currently the leading indication for liver transplantation (LT) in both the United State of America (USA) and Brazil, mainly in the State of Sao Paulo accounting for over 30% and 40% of all transplants annually, respectively (8,9). However, treatment for chronic HCV infection, with elimination of HCV infection, has revolutionized in the past 5 years with the approval of second-generation direct-acting antiviral agents.

The number of patients on the liver transplantation waiting list (LTWL) in the State of Sao Paulo jumped 2.71-fold in the past ten years, almost 50% of them due to HCV consequently the number of deaths on LTWL moved to a higher level increasing 2.09-fold [7-11].

Our aim is to analyze, through a mathematical model, the potential impact of HCV antiviral therapy on the liver transplantation waiting list (LTWL) in the State of Sao Paulo, Brazil.

Materials and Methods

This is a theoretical work and we used mathematical models designed to mimic the LTWL’s dynamics and which represent improvements on works previously published. In previous papers Chaib et al. [3-5], projected the size of the waiting list, L, by taking into account the incidence of new patients per year, l, the number of transplantations carried out in that year, Tr, and the number of patients that died in the waiting list, D. The dynamics of the waiting list is given by the recurrent equation:
\[ L_{t+1} = L_t + I_t - D_t - Tr_t \] (1)

that is, the list size at time \( t+1 \) is equal to the size of the list at the time \( t \) plus the new patients getting into the list at time \( t \), minus those patients who died in the waiting list at time \( t \), and minus those patients who received a graft at time \( t \). The variables \( I_t \) and \( D_t \) from 2006 onward were projected by fitting an equation by maximum likelihood, in the same way that we did for \( Tr_t \).

In this paper we improved the list dynamics by considering a continuous-time model as follows:

\[ \frac{dL(t)}{dt} = (\beta - \alpha - Tr)L(t) \] (2)

where \( \beta \) is the incidence rate of patients with the model for end-stage liver disease (MELD) criteria to get into the LTWL, \( \alpha \) is the death rate and \( Tr \) is the transplantation rate of patients in the LTWL, respectively. We used the Latin Hypercube sampling method [7], to find the values of the parameters that would explain the observed data.

Equation (2) has the following solution:

\[ L(t) = L(0)e^{-(\beta - \alpha - Tr)t} \] (3)

Data used in the work has been collected in the Service of Transplantation of the State Secretary of Health of Sao Paulo.

Ethical issues

This work has been approved by the Institutional Review Board of the School of Medicine, University of Sao Paulo, under the protocol number 2018-3954-7.

Results

Table 1 shows the value of the variables that entered the model. From the time variation in each of the variables, we estimated the rates of equation (2).

Figure 1 shows a comparison between the actual number of patients in the liver transplantation waiting-list from 2006 until 2017, an exponential fitting and the integral of equation (2).

As can be observed in the figure, the set of parameters used retrieves the actual data with the same accuracy as the exponential fitting. This should be expected since the solution of equation (1) is also an exponential function (equation (2)). However, the remarkable tally of the models output with the exponential fitting was obtained by optimizing the value of the parameters through the latin hypercube sampling technique used.

We the projected the result of equation (3) for the next 30 years, under the assumption that all the conditions would remain the same. Next, we introduced the anti–HCV treatment, which was assumed to halve the incidence of patients in the LTWL and that the recovery of patients in the list would triple.

The liver transplantation rate was assumed to not be affected by the anti–HCV treatment. Figure 2 shows the results of this simulation.

It can be seen from figure 2 that the anti–HCV treatment would have a remarkable impact on the size of the LTWL, dropping from around 24 thousand patients to around 1.2 thousand.

Table 1: Value of the variables that entered into the model

| Year | Previous # Patients in the LTWL | Incidence of New cases per year | Number of Transplants Recovered | Deaths |
|------|--------------------------------|-------------------------------|---------------------------------|--------|
| 1    | 4183                           | 1565                          | 510                             | 24     | 840   |
| 2    | 4013                           | 1022                          | 440                             | 44     | 708   |
| 3    | 4165                           | 1212                          | 545                             | 54     | 461   |
| 4    | 4266                           | 1287                          | 693                             | 45     | 448   |
| 5    | 4544                           | 1415                          | 744                             | 37     | 356   |
| 6    | 5023                           | 1576                          | 688                             | 15     | 394   |
| 7    | 5537                           | 1490                          | 599                             | 18     | 359   |
| 8    | 5998                           | 1520                          | 653                             | 12     | 394   |
| 9    | 6262                           | 1378                          | 665                             | 16     | 433   |
| 10   | 6643                           | 1451                          | 655                             | 19     | 396   |
| 11   | 6916                           | 1316                          | 623                             | 21     | 399   |
| 12   | 7181                           | 1385                          | 620                             | 28     | 472   |

Figure 1: Number of patients in the LTWL since 2006. Real data (blue) is compared with the simple fitting procedure (green) and the model (equation (3), Red).

Figure 2: Impact of Anti-HCV treatment on the size of the LTWL. Red dots represent real data, gross-dotted line represents the projection of the size of the LTWL in the absence of treatment and finely-dotted line the theoretical reduction in the size of the LTWL as a result of treatment introduce at time 12.5 years.
The risk for developing cirrhosis 20 years after initial HCV cirrhosis is currently the cases in an affected community because HCV-related end-stage liver failure. It represents an important health issue. We hope that this mathematical model can represent an important step in understanding the phenomenon and to provide tools of predictive capacity that may be used to guide decision-making, in particular in critical health issues such as liver transplantation. We hope that this model may be of clinical use related to the optimal distribution of anti-HCV treatment as a control tool to end-stage liver failure.

Conclusion

Our mathematical model demonstrates that anti-HCV therapy would have a remarkable impact on the size of the LTWL, in the State of Sao Paulo, dropping from twenty-four thousand to approximately twelve hundred patients in the next 30 years.

Author contributions

Chaib E, Pessoa JLE, Medeiros M and Massad E designed the research; Pessoa JLE, Medeiros M performed the research; Chaib E, Medeiros M and Massad E analyzed the data; Chaib E and Massad E wrote the paper; Chaib E, Pessoa JLE, Medeiros M and Massad E revised the manuscript prior to submission.

References

1. Carbone M, Neuberger J (2010) Liver transplantation for hepatitis C and alcoholic liver disease Journal of Transplantation Volume, Article ID 893893. Link: https://goo.gl/GoWxuS
2. Hajarizadeh B, Grebely J, Dore GJ (2013) Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10: 553–562. Link: https://goo.gl/hkWqdf
3. Machado MCC (1972) Editorial: Transplantation of the liver. Rev Hosp Clin Fac Med S Paulo, 27.
4. Chaib E, Massad E (2008) The potential impact of using donations after cardiac death on the liver transplantation program and waiting list in the state of Sao Paulo, Brazil. Liver Transpl 14: 1732-1736. Link: https://goo.gl/BAIHXH
5. Chaib E, Massad E (2008) Expected number of deaths in the liver transplantation waiting list in the state of Sao Paulo, Brazil. Transpl Int 21: 290-291. Link: https://goo.gl/tVvns1
6. Petruzzelli A, Marigliano S, Loquerio G, Cacciapuoti C (2016) Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer 11: 53. Link: https://goo.gl/IDjUvg
7. Moyer VA (2013) U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 159: 349–357. Link: https://goo.gl/mFpXDD
8. Chaib E, Massad E (2005) Liver transplantation: waiting list dynamics in the state of São Paulo, Brazil. Transplant Proc 37: 4329-4330. Link: https://goo.gl/wR5Vps
9. Chaib E, Massad E (2007) Comparing the dynamics of kidney and liver transplantation waiting list in the state of São Paulo, Brazil. Transplantation 84:1209-1211. Link: https://goo.gl/TS9phM
10. Morgan RL, Baack B, Smith BD, Yartel A, Pitas M, et al. (2013) Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158: 329-337. Link: https://goo.gl/xpzdXK
11. Crespo G, Marfilo Z, Navasa M, Forns X (2012) Viral hepatitis in liver transplantation. Gastroenterology 142: 1373–1383. Link: https://goo.gl/Yo4qm
12. Massad E, Coutinho FA, Chaib E, Burattini MN (2009) Cost-effectiveness analysis of a hypothetical hepatitis C vaccine compared to antiviral therapy. Epidemiol Infect 137: 241-249. Link: https://goo.gl/5Ln5u2
13. Yu ML, Chuang WL (2009) Treatment of chronic hepatitis C in Asia: when East meets west. J Gastroenterol Hepatol 24: 336-345. Link: https://goo.gl/QxqoX2

Citation: Chaib E, Erbs Pessoa JLE, Medeiros M, Massad E (2018) Impact of HCV antiviral therapy on the Liver Transplantation Waiting-List assessed by mathematical models. J Surg Surgical Res 5(1): 001-004. DOI: http://doi.org/10.17352/2455-2968.000058
14. Lawrence SP (2000) Advances in the treatment of hepatitis C. Adv Intern Med 45: 65-105. Link: https://goo.gl/AM68Yp

15. Chaib E, de Oliveira MC, Galvão FH, Silva FD, D’Albuquerque LA, et al. (2010) Theoretical impact of an anti-HCV vaccine on the annual number of liver transplantation. Med Hypotheses 75: 324-327. Link: https://goo.gl/EB7j9C

16. Chaib E, Coimbra BG, Galvão FH, Tatebe ER, Shinzato MS, et al. (2012) Does anti-hepatitis B virus vaccine make any difference in long-term number of liver transplantation? Clin Transplant 26: E590-595. Link: https://goo.gl/jvo7vp

17. Amaku M, Coutinho FA, Chaib E, Massad E (2013) The impact of hepatitis A virus infection on hepatitis C virus infection: a competitive exclusion hypothesis. Bull Math Biol 75: 82-93. Link: https://goo.gl/3ifGi3

18. Chaib E, Amaku M, Coutinho FA, Lopez LF, Burattini MN, et al. (2013) A mathematical model for optimizing the indications of liver transplantation in patients with hepatocellular carcinoma. Theor Biol Med Model 10: 60. Link: https://goo.gl/X3B3qK

19. Amaku M, Burattini MN, Chaib E, Coutinho FAB, Greenhalgh D, et al. (2017) Estimating the prevalence of infectious diseases from under-reported age-dependent compulsorily notification databases. Theor Biol Med Model 14: 23. Link: https://goo.gl/LLCQ7h